Alvotech Earnings Call Balances Risk and Growth

Alvotech ((ALVO)) has held its Q1 earnings call. Read on for the main highlights of the call.

Alvotech’s latest earnings call painted a cautiously optimistic picture, with management stressing long‑term growth over short‑term pain. Executives highlighted a robust biosimilar pipeline, improving EBITDA margins and growing commercial traction, even as they acknowledged a sharp revenue drop, thin product margins, cash pressure and ongoing regulatory scrutiny that could sway near‑term performance.

Pipeline and Regulatory Progress

Alvotech underscored steady advances across its biosimilar pipeline, despite regulatory headwinds that have slowed revenue. Management said resubmissions of BLAs for biosimilars to Simponi, Eylea, Prolia and Xgeva are nearly complete, while EMA filings for AVT16 and AVT80 are in, and AVT29 timelines remain on track for a 2026 EMA submission and a 2028 U.S. filing.

Commercial Momentum and Market Share Gains

On the commercial front, Alvotech highlighted AVT02 as the fastest‑growing Humira biosimilar in the U.S., already capturing about 10% market share. The company’s footprint now spans more than 90 countries, and new approvals for AVT03, AVT05 and AVT06 are starting to add incremental revenue in Europe, the U.K. and Japan, supporting the growth narrative.

Manufacturing Diversification Agreement

To buttress supply security and support future launches, Alvotech inked a strategic manufacturing pact with Fujifilm Biotechnologies. A technology transfer is underway, with U.S. product supply expected from the second half of 2027, which should diversify capacity, reduce single‑site risk and underpin the company’s anticipated expansion in key markets.

Adjusted EBITDA Improvement

Profitability trends showed progress, with adjusted EBITDA rising to $24 million in Q1 2026 from $21 million a year earlier. The EBITDA margin improved to 23% from 15%, an eight‑point gain that management attributes to disciplined cost control and a balanced revenue mix, even amid softer top‑line performance.

Gross Margin Stability

Gross margin held at a solid 57% in the quarter, edging up slightly versus last year despite operational headwinds. Executives pointed to a balanced contribution from product and licensing income as a stabilizing factor, arguing that this mix demonstrates the underlying earnings power of the platform once manufacturing fully normalizes.

Quarterly Revenue Decline

The headline negative was a 20% year‑on‑year drop in Q1 revenues to $106 million, which management linked to a deliberate slowdown in manufacturing throughput. Facility upgrades and responses to regulatory findings constrained output, and the company acknowledged that these actions, while strategic, are weighing on near‑term growth.

Low Product Margin and Throughput Impact

Product profitability took a hit, with product margin falling to just 11% in the quarter. Reduced throughput during factory enhancements in 2025 and early 2026 meant higher fixed‑cost absorption per unit, dragging margins and underscoring the sensitivity of earnings to volume recovery once regulatory issues are resolved.

Negative Operating Cash Flow and Limited Cash Balance

Cash dynamics remain a key watchpoint, as operating cash flow was negative $25 million and cash on hand stood at $64 million at quarter‑end. With $39 million invested in intangibles and continued spending on development, management conceded that liquidity is tight in the near term until operations scale back up.

High Quarterly Net Interest Payments

Alvotech also flagged sizable financing costs, with net interest payments around $35 million per quarter following a shift from PIK to cash interest in mid‑2025. These recurring outflows add pressure to the balance sheet and heighten the importance of meeting their targets for scaling revenue and improving free cash flow.

Regulatory Overhang and Inspection‑Driven Delay

The regulatory backdrop remains a swing factor, as prior complete response letters and an ongoing GMP inspection at the Reykjavik site have forced caution. Management said they intentionally slowed production to “de‑risk” compliance and operations, accepting short‑term revenue disruption in exchange for a cleaner path to approvals, though timing still carries some uncertainty.

Revenue Mix and Lumpy Licensing Income

Alvotech’s Q1 results underscored the volatility of its revenue mix, with roughly half of the $106 million total coming from licensing and milestones and half from product sales. Executives cautioned that such licensing income is inherently lumpy, which can make quarterly results choppy even when underlying demand for its biosimilars is building.

Guidance and Longer‑Term Growth Outlook

Management reiterated full‑year 2026 guidance of $650–700 million in revenue and $180–220 million in adjusted EBITDA, with Q4 flagged as the strongest quarter and a goal of positive free cash flow by year‑end. They see 2027 as a step‑change year, helped by higher manufacturing output, margin expansion, key BLA resubmissions after the current FDA inspection and added U.S. supply from Fujifilm starting in the second half of 2027.

Alvotech’s earnings call ultimately balanced near‑term caution with longer‑term confidence in its biosimilar strategy. While regulatory risks, cash constraints and weak product margins weigh on the story today, a growing global footprint, improving EBITDA and a deep late‑stage pipeline position the company as a high‑risk, potentially high‑reward name for investors tracking the biosimilar space.